U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H33NO3.C6H8O7
Molecular Weight 527.6044
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXELADIN CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1

InChI

InChIKey=KVKJFNUGVOFNGU-UHFFFAOYSA-N
InChI=1S/C20H33NO3.C6H8O7/c1-5-20(6-2,18-12-10-9-11-13-18)19(22)24-17-16-23-15-14-21(7-3)8-4;7-3(8)1-6(13,5(11)12)2-4(9)10/h9-13H,5-8,14-17H2,1-4H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI
Molecular Formula C20H33NO3
Molecular Weight 335.4809
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.fda.gov.ph/consumers-corner/registered-drugs-2/337707-DR-X1387

Oxeladin citrate is a cough suppressant, is a highly potent and effective drug used to treat all types of cough of various etiologies. Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. Oxeladine is a component of antitussive drug, Altussan, approved in Philippines.

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
Altussan

Approved Use

For the relief of all types of cough w/ acute and chronic inflammation due to upper and lower respiratory tract infections
PubMed

PubMed

TitleDatePubMed
High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products.
2005 Aug
Patents

Patents

US20110159100
2

Sample Use Guides

In Vivo Use Guide
Cap Adult 1 cap. Syr Adult 1 tbsp (15 mL). Childn 1 tsp (5 mL). Infant ¼-½ tsp (1.25-2.5 mL). All doses to be taken 3 hrly.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:46:31 GMT 2023
Edited
by admin
on Fri Dec 15 17:46:31 GMT 2023
Record UNII
5AEV5C340C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXELADIN CITRATE
JAN   MART.   MI   WHO-DD  
Common Name English
Oxeladin citrate [WHO-DD]
Common Name English
2-(2-DIETHYLAMINOETHOXY)ETHYL 2-ETHYL-2-PHENYLBUTYRATE DIHYDROGEN CITRATE
Systematic Name English
OXELADIN CITRATE [MI]
Common Name English
NSC-759231
Code English
OXELADIN CITRATE [MART.]
Common Name English
OXELADIN DIHYDROGEN CITRATE
Common Name English
OXELADIN HYDROGEN CITRATE [EP MONOGRAPH]
Common Name English
OXELADIN CITRATE [JAN]
Common Name English
OXELADIN HYDROGEN CITRATE
EP  
Common Name English
OXELADINE CITRATE
Common Name English
BENZENEACETIC ACID, .ALPHA.,.ALPHA.-DIETHYL-, 2-(2-(DIETHYLAMINO)ETHOXY)ETHYL ESTER, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
Systematic Name English
Code System Code Type Description
CAS
52432-72-1
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
MERCK INDEX
m8299
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY Merck Index
PUBCHEM
40384
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
ECHA (EC/EINECS)
257-910-8
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
SMS_ID
100000085506
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
EVMPD
SUB03567MIG
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
RXCUI
54239
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY RxNorm
CAS
16485-39-5
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
SUPERSEDED
ChEMBL
CHEMBL1500276
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
FDA UNII
5AEV5C340C
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
NSC
759231
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID4046608
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
DRUG BANK
DBSALT002252
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
MESH
C005461
Created by admin on Fri Dec 15 17:46:31 GMT 2023 , Edited by admin on Fri Dec 15 17:46:31 GMT 2023
PRIMARY
Related Record Type Details
Structure of OXELADIN
PARENT -> SALT/SOLVATE
Structure of ANHYDROUS CITRIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of OXELADIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966